These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571 [TBL] [Abstract][Full Text] [Related]
5. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908 [TBL] [Abstract][Full Text] [Related]
6. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167 [TBL] [Abstract][Full Text] [Related]
7. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies. Ren X; Ma W; Lu H; Yuan L; An L; Wang X; Cheng G; Zuo S Cancer Immunol Immunother; 2015 Dec; 64(12):1517-29. PubMed ID: 26386966 [TBL] [Abstract][Full Text] [Related]
8. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E Front Immunol; 2020; 11():581468. PubMed ID: 33193388 [TBL] [Abstract][Full Text] [Related]
9. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy. Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655 [TBL] [Abstract][Full Text] [Related]
10. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403 [TBL] [Abstract][Full Text] [Related]
11. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797 [TBL] [Abstract][Full Text] [Related]
12. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629 [TBL] [Abstract][Full Text] [Related]
13. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279 [TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448 [TBL] [Abstract][Full Text] [Related]
15. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells. Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221 [TBL] [Abstract][Full Text] [Related]
16. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Lo AS; Ma Q; Liu DL; Junghans RP Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472 [TBL] [Abstract][Full Text] [Related]
17. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology. Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457 [TBL] [Abstract][Full Text] [Related]
18. [Specific immune cell therapy against ovarian cancer in vivo and in vitro]. Chang XH; Cheng HY; Cheng YX; Ye X; Guo HF; Fu TY; Zhang L; Zhang G; Cui H Ai Zheng; 2008 Dec; 27(12):1244-50. PubMed ID: 19079987 [TBL] [Abstract][Full Text] [Related]
19. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells. Ma C; Wei Y; Liu Q; Xin Y; Cao G; Wang X; Yang P Biomed Pharmacother; 2019 Sep; 117():109167. PubMed ID: 31387180 [TBL] [Abstract][Full Text] [Related]
20. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]